Cumberland Pharmaceuticals CPIX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.29M-130% | -$1.43M+26.7% | -$1.95M-165% | -$735.21K-159% | $1.25M+166% | ||
| $1.28M+22.5% | $1.04M+0.4% | $1.04M+0.4% | $1.03M+0.2% | $1.03M-31.1% | ||
| $106.84K-37.9% | $172.16K+112% | $81.26K+0.7% | $80.69K+8.7% | $74.21K-0.8% | ||
| $5.17K-27.1% | $7.1K+32.4% | $5.36K0.0% | $5.36K0.0% | $5.36K-40.0% | ||
| -$2.68M-141% | $6.51M+5,630% | $113.69K+166% | -$171.01K+85.9% | -$1.21M-410% | ||
| -$703.86K— | $0+100% | -$630.41K+25.9% | -$850.8K+12.1% | -$967.4K+27.6% | ||
| -$1.35M-117% | $8.04M+1,076% | $684.22K+148% | -$1.42M-136% | -$600.04K-85.0% | ||
| -$384.15K-137% | $1.05M+687% | -$178.94K+69.1% | -$579.65K-860% | -$60.37K— | ||
| -$202.82K-56.9% | -$129.23K+63.1% | -$349.78K-218% | $295.31K+200% | -$293.94K— | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | ||
| -$225.35K-29.5% | -$173.98K+21.5% | -$221.68K-0.3% | -$220.95K-0.7% | -$219.49K-109% | ||
| -$228.97K— | —— | $9.65K-75.0% | $38.6K-14.2% | $44.98K+109% | ||
| $387.03K+12,698% | $3.02K-98.4% | $187.18K-77.8% | $843.8K-78.4% | $3.9M— | ||
| $0— | $0-100% | $23.79K-10.2% | $26.49K-44.4% | $47.63K+1,986% | ||
| $19.16K-56.3% | $43.84K+419% | $8.45K-39.3% | $13.91K-23.6% | $18.2K-25.8% | ||
| -$61.17K+98.0% | -$3.07M-345% | -$690.84K— | $0+100% | -$1.23M— | ||
| $61K— | $0-100% | $10.44K+45.6% | $7.17K-97.1% | $245.87K+150% | ||
| $0— | —— | —— | —— | $10.04M+58.9% | ||
| $702.3K+3.0% | $681.74K+81.1% | $376.44K+162% | $143.63K-71.9% | $511.13K+10.0% | ||
| -$763.3K-12.0% | -$681.74K-76.2% | -$386.88K-157% | -$150.8K+97.3% | -$5.53M— | ||
| -$437.45K+88.3% | -$3.75M-321% | -$890.54K— | —— | -$2.86M— | ||
| —— | $110.42K0.0% | $110.42K0.0% | $110.42K0.0% | $110.42K-22.4% | ||
| —— | -$881.250.0% | -$881.250.0% | -$881.250.0% | -$881.25-124% | ||
| $5.17K-27.1% | $7.1K+32.4% | $5.36K0.0% | $5.36K0.0% | $5.36K-40.0% | ||
| -$228.97K— | —— | $9.65K-75.0% | $38.6K-14.2% | $44.98K+109% | ||
| —— | -$3.31K0.0% | -$3.31K0.0% | -$3.31K0.0% | -$3.31K— | ||
| -$86.95K— | —— | $91.46K-24.8% | $121.69K+250% | -$81.18K— | ||
| -$225.35K-29.5% | -$173.98K+21.5% | -$221.68K-0.3% | -$220.95K-0.7% | -$219.49K-109% | ||
| -$202.82K-56.9% | -$129.23K+63.1% | -$349.78K-218% | $295.31K+200% | -$293.94K— | ||
| -$384.15K-137% | $1.05M+687% | -$178.94K+69.1% | -$579.65K-860% | -$60.37K— | ||
| $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | ||
| $0— | —— | —— | —— | $1.16M— | ||
| $19.16K-56.3% | $43.84K+419% | $8.45K-39.3% | $13.91K-23.6% | $18.2K-25.8% | ||
| $42.02K— | —— | —— | —— | $0— | ||
| —— | $500K0.0% | $500K0.0% | $500K0.0% | $500K— | ||
| $0— | —— | —— | —— | -$5.27M— | ||
| $0— | —— | —— | —— | $10.04M+58.9% | ||
| —— | $15.50.0% | $15.50.0% | $15.50.0% | $15.5+100% | ||
| -$225.35K-29.5% | -$173.98K+21.5% | -$221.68K-0.3% | -$220.95K-0.7% | -$219.49K-109% | ||
| —— | $500K0.0% | $500K0.0% | $500K0.0% | $500K— | ||
| $702.3K+3.0% | $681.74K+81.1% | $376.44K+162% | $143.63K-71.9% | $511.13K+10.0% | ||
| —— | $1.18K0.0% | $1.18K0.0% | $1.18K0.0% | $1.18K+792% | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| —— | $209.03K0.0% | $209.03K0.0% | $209.03K0.0% | $209.03K-3.2% | ||
| —— | -$881.250.0% | -$881.250.0% | -$881.250.0% | -$881.25-124% | ||
| $387.03K+12,694% | $3.03K-98.1% | $163.39K-80.0% | $817.32K-78.8% | $3.85M— | ||
| $387.03K+12,694% | $3.03K-98.1% | $163.39K-80.0% | $817.32K-78.8% | $3.85M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cumberland Pharmaceuticals generate?
- Cumberland Pharmaceuticals (CPIX) generated $1.4M in operating cash flow over the trailing twelve months.
- What is Cumberland Pharmaceuticals's free cash flow?
- After $50.3K of capital expenditures, Cumberland Pharmaceuticals's free cash flow was $1.4M over the trailing twelve months, down 23.9% year over year.
- Where does Cumberland Pharmaceuticals's cash flow data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
